Evaluation of the relationship of cholinergic metabolites in urine and urgency urinary incontinence.
Acetylcholine
Choline
Urgency incontinence
Journal
International urogynecology journal
ISSN: 1433-3023
Titre abrégé: Int Urogynecol J
Pays: England
ID NLM: 101567041
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
04
12
2020
accepted:
24
03
2021
pubmed:
6
4
2021
medline:
24
5
2022
entrez:
5
4
2021
Statut:
ppublish
Résumé
To investigate differences in urine cholinergic metabolites in women with urinary urgency incontinence (UUI) and responders (R) and non-responders (NR) to anti-cholinergic medications (AC). Patients with UUI and age-matched controls were evaluated pre- and post-treatment using OABSS, UDI-6 and IIQ-7. Controls were defined as having a cumulative OABSS of zero. Patients with UUI were treated with AC and followed for 12 weeks. Responders were those with a > 50% decrease in the total OABSS score. Urine samples were collected from all participants for evaluation. Metabolite detection was accomplished using commercial assay kits. Wilcoxon-rank sum test and Fisher's exact test were used to express differences between groups. Spearman's rho correlation coefficient was used to determine the relationship between acetylcholine (Ach), choline (Ch), acetylcholinesterase (AchE) and questionnaire scores. We recruited 39 with UUI and 33 controls. We found concentrations of Ch [29.0 (IQR: 24.2-42.5) μmol vs. 15.2 (IQR: 7.5-24.1) μmol] and Ach [65.8 (IQR: 30.4-101.8) nmol and 33.1 (IQR: 11.9-43.8) nmol] were higher in the UUI group compared to controls (p = 0.003 and p < 0.001, respectively] and no differences in AchE concentrations. In the UUI group, 43.6% responded to AC after 12 weeks of therapy. There were no differences in Ch or AchE levels between R and NR; Ach levels were higher in the R group [82.1 nmol (IQR: 54.8-118.1) vs. 50.3 nmol (IQR: 29.9-68.2), p = 0.007]. Ch and Ach were positively associated with pre-treatment OABSS parameters. Urine Ach is higher in responders to anti-cholinergic therapy, and urine cholinergic metabolites were higher in the UUI patients compared to controls.
Identifiants
pubmed: 33818647
doi: 10.1007/s00192-021-04785-z
pii: 10.1007/s00192-021-04785-z
pmc: PMC8020620
doi:
Substances chimiques
Cholinergic Agents
0
Cholinergic Antagonists
0
Acetylcholinesterase
EC 3.1.1.7
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1165-1174Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR002548
Pays : United States
Organisme : Clinical and Translational Science Collaborative of Cleveland, School of Medicine, Case Western Reserve University (US)
ID : UL1TR002548
Informations de copyright
© 2021. The International Urogynecological Association.
Références
Stewart WF, Corey R, Herzog AR, et al. Prevalence of overactive bladder in women: results from the NOBLE program. Int Urogynecol J. 2001;12:S66.
Lukacz ES, Santiago-Lastra Y, Albo ME, Brubaker L. Urinary incontinence in women: a review. JAMA. 2017;318(16):1592–604. https://doi.org/10.1001/jama.2017.12137 .
doi: 10.1001/jama.2017.12137
pubmed: 29067433
Older population and aging. https://www.census.gov/topics/population/older-aging.html . Accessed October 29 2020.
Coyne KS, Kvasz M, Ireland AM, Milsom I, Kopp ZS, Chapple CR. Urinary incontinence and its relationship to mental health and health-related quality of life in men and women in Sweden, the United Kingdom, and the United States. Eur Urol. 2012;61(1):88–95. https://doi.org/10.1016/j.eururo.2011.07.049 .
doi: 10.1016/j.eururo.2011.07.049
pubmed: 21831517
Peyronnet B, Mironska E, Chapple C, Cardozo L, Oelke M, Dmochowski R, et al. A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment. Eur Urol. 2019;75(6):988–1000. https://doi.org/10.1016/j.eururo.2019.02.038 .
doi: 10.1016/j.eururo.2019.02.038
pubmed: 30922690
Chan SS, Chan DK, Pang SM, Lam ST, Lao TT, Choy KW. Urinary incontinence should be added to the manifestation in women with Marfan syndrome. Int Urogynecol J. 2010;21(5):583–7. https://doi.org/10.1007/s00192-009-1078-4 .
doi: 10.1007/s00192-009-1078-4
pubmed: 20066398
Smith AL. Understanding overactive bladder and urgency incontinence: what does the brain have to do with it? F1000Res. 2018;7:F1000 Faculty Rev-1869. https://doi.org/10.12688/f1000research.16418.1 .
doi: 10.12688/f1000research.16418.1
pubmed: 30631425
pmcid: 6281005
Speich JE, Tarcan T, Hashitani H, Vahabi B, McCloskey KD, Andersson KE, et al. Are oxidative stress and ischemia significant causes of bladder damage leading to lower urinary tract dysfunction? Report from the ICI-RS 2019. Neurourol Urodyn. 2020;39(Suppl 3):S16–22. https://doi.org/10.1002/nau.24313 .
doi: 10.1002/nau.24313
pubmed: 32056281
Araklitis G, Baines G, da Silva AS, Robinson D, Cardozo L. Recent advances in managing overactive bladder. F1000Res. 2020;9:F1000 Faculty Rev-1125. https://doi.org/10.12688/f1000research.26607.1 .
doi: 10.12688/f1000research.26607.1
pubmed: 32968482
pmcid: 7489273
Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment 2019. J Urol. 2019;202(3):558–63. https://doi.org/10.1097/JU.0000000000000309 .
doi: 10.1097/JU.0000000000000309
pubmed: 31039103
Bedoya-Ronga A, Currie I. Improving the management of urinary incontinence. Practitioner. 2014;258(1769):21–4. 2-3.
pubmed: 24791407
Rohloff M, Peifer G, Thompson JH. Patient navigation for overactive bladder improves access to care. Int Urogynecol J. 2020;31(5):1007–12. https://doi.org/10.1007/s00192-019-04085-7 .
doi: 10.1007/s00192-019-04085-7
pubmed: 31463529
Antunes-Lopes T, Cruz F. Urinary biomarkers in overactive bladder: revisiting the evidence in 2019. Eur Urol Focus. 2019;5(3):329–36. https://doi.org/10.1016/j.euf.2019.06.006 .
doi: 10.1016/j.euf.2019.06.006
pubmed: 31231010
Sheyn D, Hijaz AK, Hazlett FE Jr, El-Nashar S, Mangel JM, Li X, et al. Evaluation of choline and acetylcholine levels in responders and nonresponders to anticholinergic therapy for overactive bladder syndrome. Female Pelvic Med Reconstr Surg. 2019. https://doi.org/10.1097/SPV.0000000000000787 .
Sheyn D, Hijaz AK, Hazlett FE Jr, Dawodu K, El-Nashar S, Mangel JM, et al. Evaluation of urine choline levels in women with and without overactive bladder syndrome. Female Pelvic Med Reconstr Surg. 2020;26(10):644–8. https://doi.org/10.1097/SPV.0000000000000639 .
doi: 10.1097/SPV.0000000000000639
pubmed: 30212388
Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. Strobe initiative. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Prev Med. 2007;45(4):247–51.
doi: 10.1016/j.ypmed.2007.08.012
Homma Y, Yoshida M, Seki N, Yokoyama O, Kakizaki H, Gotoh M, et al. Symptom assessment tool for overactive bladder syndrome—overactive bladder symptom score. Urology. 2006;68(2):318–23. https://doi.org/10.1016/j.urology.2006.02.042 .
doi: 10.1016/j.urology.2006.02.042
pubmed: 16904444
Uebersax JS, Wyman JF, Shumaker SA, McClish DK, Fantl JA. Short forms to assess life quality and symptom distress for urinary incontinence in women: the incontinence impact questionnaire and the urogenital distress inventory. Continence program for women research group. Neurourol Urodyn. 1995;14(2):131–9. https://doi.org/10.1002/nau.1930140206 .
doi: 10.1002/nau.1930140206
pubmed: 7780440
Zhao YR, Liu WZ, Guralnick M, Niu WJ, Wang Y, Sun G, et al. Predictors of short-term overactive bladder symptom improvement after transurethral resection of prostate in men with benign prostatic obstruction. Int J Urol. 2014;21(10):1035–40.
doi: 10.1111/iju.12482
Edmands WM, Ferrari P, Scalbert A. Normalization to specific gravity prior to analysis improves information recovery from high resolution mass spectrometry metabolomic profiles of human urine. Anal Chem. 2014;86(21):10925–31. https://doi.org/10.1021/ac503190m .
doi: 10.1021/ac503190m
pubmed: 25285402
Hsiao SM, Lin HH, Kuo HC. Factors associated with a better therapeutic effect of solifenacin in patients with overactive bladder syndrome. Neurourol Urodyn. 2014;33(3):331–4. https://doi.org/10.1002/nau.22394 .
doi: 10.1002/nau.22394
pubmed: 23494586
Wagg A, Compion G, Fahey A, Siddiqui E. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012;110(11):1767–74. https://doi.org/10.1111/j.1464-410X.2012.11023.x .
doi: 10.1111/j.1464-410X.2012.11023.x
pubmed: 22409769
Yamada S, Ito Y, Nishijima S, Kadekawa K, Sugaya K. Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder. Pharmacol Ther. 2018;189:130–48. https://doi.org/10.1016/j.pharmthera.2018.04.010 .
doi: 10.1016/j.pharmthera.2018.04.010
pubmed: 29709423
Lips KS, Wunsch J, Zarghooni S, Bschleipfer T, Schukowski K, Weidner W, et al. Acetylcholine and molecular components of its synthesis and release machinery in the urothelium. Eur Urol. 2007;51(4):1042–53. https://doi.org/10.1016/j.eururo.2006.10.028 .
doi: 10.1016/j.eururo.2006.10.028
pubmed: 17084519
Fry CH, Vahabi B. The role of the mucosa in normal and abnormal bladder function. Basic Clin Pharmacol Toxicol. 2016;119(Suppl 3):57–62. https://doi.org/10.1111/bcpt.12626 .
doi: 10.1111/bcpt.12626
pubmed: 27228303
pmcid: 5555362
Zeisel SH, da Costa KA. Choline: an essential nutrient for public health. Nutr Rev. 2009;67(11):615–23. https://doi.org/10.1111/j.1753-4887.2009.00246.x .
doi: 10.1111/j.1753-4887.2009.00246.x
pubmed: 19906248
Ueland PM. Choline and betaine in health and disease. J Inherit Metab Dis. 2011;34(1):3–15. https://doi.org/10.1007/s10545-010-9088-4 .
doi: 10.1007/s10545-010-9088-4
pubmed: 20446114
Hilt EE, Putonti C, Thomas-White K, Lewis AL, Visick KL, Gilbert NM, et al. Aerococcus urinae isolated from women with lower urinary tract symptoms: In Vitro aggregation and genome analysis. J Bacteriol. 2020;202(13):e00170–20. https://doi.org/10.1128/JB.00170-20 .
doi: 10.1128/JB.00170-20
pubmed: 32284319
pmcid: 7283593
Wu P, Chen Y, Zhao J, Zhang G, Chen J, Wang J, et al. Urinary microbiome and psychological factors in women with overactive bladder. Front Cell Infect Microbiol. 2017;7:488. https://doi.org/10.3389/fcimb.2017.00488 .
doi: 10.3389/fcimb.2017.00488
pubmed: 29230385
pmcid: 5712163
Angelini KJ. An integrative review of current research on the role of the female urinary microbiota in overactive bladder symptoms. Urol Nurs. 2017;37(2):94–100.
doi: 10.7257/1053-816X.2017.37.2.94
Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci. 2012;13(10):701–12. https://doi.org/10.1038/nrn3346 .
doi: 10.1038/nrn3346
pubmed: 22968153
Hsiao SM, Liao CH, Lin HH, Kuo HC. Duration of antimuscarinic administration for treatment of overactive bladder before which one can assess efficacy: an analysis of predictive factors. Int Neurourol J. 2015;19(3):171–7. https://doi.org/10.5213/inj.2015.19.3.171 .
doi: 10.5213/inj.2015.19.3.171
pubmed: 26620899
pmcid: 4582089
Wang Y, Shi C, Wang Y, Jiao W, Wang X, Zhang J, et al. The correlation between severity of overactive bladder symptoms with female sexual dysfunction and sexual satisfaction of partners. Urol Int. 2020;11:1–7. https://doi.org/10.1159/000508764 .
doi: 10.1159/000508764
Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011;108(7):1132–8. https://doi.org/10.1111/j.1464-410X.2010.09993.x .
doi: 10.1111/j.1464-410X.2010.09993.x
pubmed: 21231991